Title:
NOVEL TRANSPLANTATION CELLS HAVING REDUCED IMMUNOGENICITY
Document Type and Number:
WIPO Patent Application WO/2022/010220
Kind Code:
A1
Abstract:
The present invention relates to a composition for suppressing immunogenicity in mammalian cells, and a method for preparing mammalian cells having low immunogenicity by using same. The present invention relates to cells to undergo allogeneic transplantation for a therapeutic purpose, such as stem cells or immunocytes, the cells being effectively usable as an efficient cell therapeutic agent having, in the body of a recipient, minimized immunorejection and activity that is maintained for a long time.
More Like This:
| WO/2003/039438 | PNA-CONJUGATES FOR TREATING CHRONIC MYELOID LEUKAEMIA (CML) |
| JP2022521463 | New fish totivirus |
| WO/2023/012237 | COMPOUND AND METHOD FOR A SPECIFIC TARGETING OF THE HAX1 GENE |
Inventors:
KIM HYUN AH (KR)
KIM SEUNG MIN (KR)
HER JUNG HYUN (KR)
CHO SUNGLIM (KR)
KIM HYOJIN (KR)
LIM HOYONG (KR)
CHO SUNGYOO (KR)
HWANG YU KYEONG (KR)
KIM SEUNG MIN (KR)
HER JUNG HYUN (KR)
CHO SUNGLIM (KR)
KIM HYOJIN (KR)
LIM HOYONG (KR)
CHO SUNGYOO (KR)
HWANG YU KYEONG (KR)
Application Number:
PCT/KR2021/008554
Publication Date:
January 13, 2022
Filing Date:
July 06, 2021
Export Citation:
Assignee:
GC CELL CORP (KR)
International Classes:
C12N15/113; A61K35/17; A61K48/00; C07K14/74; C12N5/0783; C12N9/22; C12N15/10
Domestic Patent References:
| WO2017093969A1 | 2017-06-08 | |||
| WO2014186585A2 | 2014-11-20 |
Foreign References:
| KR20200074954A | 2020-06-25 | |||
| KR20170002381A | 2017-01-06 | |||
| KR20160018425A | 2016-02-17 | |||
| US20050196404A1 | 2005-09-08 |
Other References:
XU HUAIGENG; WANG BO; ONO MIYUKI; KAGITA AKIHIRO; FUJII KAHO; SASAKAWA NORIKO; UEDA TATSUKI; GEE PETER; NISHIKAWA MISATO; NOMURA M: "Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility", CELL STEM CELL, ELSEVIER, CELL PRESS, AMSTERDAM, NL, vol. 24, no. 4, 1 January 1900 (1900-01-01), AMSTERDAM, NL , pages 566, XP085654753, ISSN: 1934-5909, DOI: 10.1016/j.stem.2019.02.005
BLOOD CELLS MOLECULES & DISEASE, vol. 33, 2004, pages 261 - 266
KIM, HS, HANYANG MED REV, vol. 33, 2013, pages 59 - 64
ROMAGNE F, VIVIER E.,F1000 MED REP, vol. 3, 2011, pages 9
WALDMANN TA., NAT REV IMMUNOL, vol. 6, 2006, pages 595 - 601
SCHEIT: "Nucleotide Analogs", 1980, JOHN WILEY
UHLMANPEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543 - 584
HUANG ET AL., COMP. APPL. BIOSCI, vol. 8, 1992, pages 155 - 65
PEARSON ET AL., METH. MOL. BIOL, vol. 24, 1994, pages 307 - 31
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ROMAGNE FVIVIER E., F1000 MED REP, vol. 3, 2011, pages 9
LOCKETT LJ ET AL., CLIN. CANCER RES., vol. 3, 1997, pages 2075 - 2080
WANG G ET AL., J. CLIN. INVEST, vol. 104, no. 11, 1999, pages 55 - 62
CHAMBER R. ET AL., PROC. NATL. ACT. SCI USA, vol. 92, 1995, pages 1411 - 1415
PUHLMANN M. ET AL., HUMAN GENE THERAPY, vol. 10, 1999, pages 649 - 657
"Methods in Molecular Biology", vol. 199, 2002, HUMAN PRESS
BLOOD CELLS MOLECULES & DISEASE, vol. 33, 2004, pages 261 - 266
KIM, HS, HANYANG MED REV, vol. 33, 2013, pages 59 - 64
ROMAGNE F, VIVIER E.,F1000 MED REP, vol. 3, 2011, pages 9
WALDMANN TA., NAT REV IMMUNOL, vol. 6, 2006, pages 595 - 601
SCHEIT: "Nucleotide Analogs", 1980, JOHN WILEY
UHLMANPEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543 - 584
HUANG ET AL., COMP. APPL. BIOSCI, vol. 8, 1992, pages 155 - 65
PEARSON ET AL., METH. MOL. BIOL, vol. 24, 1994, pages 307 - 31
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ROMAGNE FVIVIER E., F1000 MED REP, vol. 3, 2011, pages 9
LOCKETT LJ ET AL., CLIN. CANCER RES., vol. 3, 1997, pages 2075 - 2080
WANG G ET AL., J. CLIN. INVEST, vol. 104, no. 11, 1999, pages 55 - 62
CHAMBER R. ET AL., PROC. NATL. ACT. SCI USA, vol. 92, 1995, pages 1411 - 1415
PUHLMANN M. ET AL., HUMAN GENE THERAPY, vol. 10, 1999, pages 649 - 657
"Methods in Molecular Biology", vol. 199, 2002, HUMAN PRESS
Attorney, Agent or Firm:
PADO IP LAW PLLC (KR)
Download PDF: